title: Pharmacokinetics of multiple-dose administration of eltenac in horses.
abstract: OBJECTIVE
  To compare pharmacokinetics of eltenac after first and last IV administrations (0.5 mg/kg), using a multiple dosing schedule.
  
  
  METHODS
  6 adult mares.
  
  
  METHODS
  Eltenac (50 mg/ml) was administered IV at a dosage of 0.5 mg/kg of body weight every 24 hours for days 0 through 4. On days 0 and 4, blood samples were collected before, then periodically for 8 hours after eltanac administration. Concentration of eltenac in plasma samples was determined by use of high-performance liquid chromatography.
  
  
  RESULTS
  On day 0, median area under the plasma eltenac concentration versus time curve (AUC) was 6.77 microg.h/ml (range, 5.61 to 8.08 microg.h/ml), median plasma clearance was 1.23 ml/min/kg (range, 1.03 to 1.40 ml/min/kg), and median steady-state volume of distribution was 191 ml/kg (range, 178 to 218 ml/kg). Median terminal half-life of eltenac was 2.36 hours (range, 2.30 to 2.98 hours). On day 4, median eltenac AUC was 6.70 microg.h/ml (range, 5.21 to 7.44 microg.h/ml), median plasma clearance was 1.23 ml/min/kg (range, 1.12 to 1.53 ml/min/kg), and median steady-state volume of distribution was 193 ml/kg (range, 172 to 205 ml/kg). Median terminal half-life of eltenac was 2.40 hours (range, 2.11 to 3.25 hours). Protein binding of eltenac, determined by ultrafiltration, was > 99% at a total plasma concentration of 36 microg/ml.
  
  
  CONCLUSIONS
  Pharmacokinetic variables determined for each horse were not different between days 0 and 4.
  
  
  CONCLUSIONS
  Under conditions of this study, there was no clinically relevant accumulation of eltenac in equine plasma or alteration of pharmacokinetic variables after multiple IV dosing of 0.5 mg/kg of eltenac.
authors.affiliation: Analytical Toxicology Laboratory, College of Veterinary Medicine, The Ohio State University, Columbus 43210-1089, USA.
authors.forename: T M
authors.initials: TM
authors.lastname: Dyke
authors.forename: R A
authors.initials: RA
authors.lastname: Sams
authors.forename: K G
authors.initials: KG
authors.lastname: Thompson
authors.forename: S M
authors.initials: SM
authors.lastname: Ashcraft
mesh_terms: D000814:Aniline Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid / Q000662:veterinary; D004334:Drug Administration Schedule / Q000662:veterinary; D004341:Drug Evaluation / Q000662:veterinary*; D005260:Female; D006736:Horses / Q000378:metabolism*; D007275:Injections, Intravenous / Q000662:veterinary; D013876:Thiophenes / Q000008:administration & dosage* / Q000493:pharmacokinetics*
chemical_list: D000814:Aniline Compounds; D000894:Anti-Inflammatory Agents, Non-Steroidal; D013876:Thiophenes; C071200:eltenac